CAJ | 학술논문

目的：体外评价带有叶酸和穿膜肽双配体的、负载紫杉醇纳米药物输送系统的生物性能。方法分别用H-F-P NPs、H-Tat-P NPs及H-F-Tat-P NPs孵育细胞，利用流式细胞仪定量评价细胞对带有不同配体纳米药物输送系统的摄取量。再用H-F-Tat-P NPs孵育细胞，利用激光共聚焦显微镜定性评价不同细胞对H-F-Tat-P NPs的摄取量。结果叶酸受体阳性表达的MDA-MB-231细胞摄取H-F-Tat-P NPs的量明显多于H-F-P NPs及H-Tat-P NPs。叶酸受体阴性表达的A549细胞摄取H-F-Tat-P NPs与H-Tat-P NPs的量多于H-F-P NPs。结论叶酸的靶向作用与穿膜肽的穿膜作用能够协同提高药物在靶细胞的聚集，进一步增强药物输送系统的治疗作用，为开发新型、高效药物输送系统提供基础。
목적：체외평개대유협산화천막태쌍배체적、부재자삼순납미약물수송계통적생물성능。방법분별용H-F-P NPs、H-Tat-P NPs급H-F-Tat-P NPs부육세포，이용류식세포의정량평개세포대대유불동배체납미약물수송계통적섭취량。재용H-F-Tat-P NPs부육세포，이용격광공취초현미경정성평개불동세포대H-F-Tat-P NPs적섭취량。결과협산수체양성표체적MDA-MB-231세포섭취H-F-Tat-P NPs적량명현다우H-F-P NPs급H-Tat-P NPs。협산수체음성표체적A549세포섭취H-F-Tat-P NPs여H-Tat-P NPs적량다우H-F-P NPs。결론협산적파향작용여천막태적천막작용능구협동제고약물재파세포적취집，진일보증강약물수송계통적치료작용，위개발신형、고효약물수송계통제공기출。
Objective To evaluate in vitro biological activities of paclitaxel nanoparticles with dual ligands. Meth-ods The cells were incubated with H-F-P NPs,H-Tat-P NPs,or H-F-Tat-P NPs,and then evaluated by using flow cytometry. Then the cells were incubated with H-F-Tat-P NPs,and evaluated by using confocal laser scanning microscopy. Results Quantitative analysis of cellular uptake of NPs by flow cytometry showed the extend of celluar uptake for A549 cell lines was:H-F-Tat-P NPs > H-Tat-P NPs > H-F-P NPs. For MDA-MB-231 cells:H-F-Tat-P NPs >H-F-P NPs> H-Tat-P NPs. Quali-tative analysis of cellular uptake of H-F-Tat-P NPs by confocal laser scanning microscopy showed the fluorescent signal of NPs in MDA-MB-231 cells was higher than that of A549 cells under the same conditions. Conclusion The strategy on nano-medicine with dual ligands can enhance the cellular uptake of drug thereby improve its chemotherapeutic efficiency. The nano-particle system could be used as a promising cancer cell specific delivery system for further investigation.